---
title: "AOD-9604"
slug: "aod-9604"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/aod-9604"
description: "AOD-9604 targets fat breakdown without affecting blood sugar or hormones. GH-fragment mechanism, clinical data, and what research shows for body comp."
---
# AOD-9604

*GH Fragment 176-191, Targeted Lipolysis Without Hormonal Side Effects*

**Category:** Body Composition  
**Format:** Lyophilized Vial  
**Amount:** 5mg  
**Purity:** >99.0% (HPLC)

## Overview

AOD-9604 (Advanced Obesity Drug-9604) is a modified fragment of human growth hormone, specifically corresponding to amino acids 176-191 of the GH molecule with an additional N-terminal tyrosine residue. This fragment was identified and developed by Professor Frank Ng and colleagues at Monash University in Melbourne, Australia, based on the discovery that the fat-metabolizing properties of growth hormone reside in a specific region of the GH molecule distinct from the regions responsible for growth-promoting, diabetogenic, and IGF-1-stimulating effects.

The fundamental innovation of AOD-9604 lies in its ability to isolate growth hormone's lipolytic (fat-burning) activity from its other biological effects. Full-length growth hormone exerts its fat-metabolizing effects through the C-terminal region (amino acids 176-191), while its growth-promoting, IGF-1-stimulating, and blood-sugar-affecting properties are mediated through different structural domains. By isolating just the C-terminal fragment and stabilizing it with a tyrosine addition, researchers created a compound that stimulates fat breakdown without the hormonal side effects associated with full GH administration.

AOD-9604's mechanism of action involves mimicking the way natural growth hormone regulates fat metabolism. It stimulates lipolysis (the breakdown of stored triglycerides into free fatty acids) through activation of hormone-sensitive lipase (HSL) in adipocytes. Simultaneously, it inhibits lipogenesis, the formation of new fat from circulating fatty acids and glucose. This dual action, enhancing fat breakdown while preventing new fat formation, creates a net reduction in adipose tissue that is more sustained than either mechanism alone.

Critically, research has demonstrated that AOD-9604 does not stimulate production of IGF-1 or affect blood sugar levels, two significant concerns with full growth hormone administration. A study published in the Journal of Endocrinology confirmed that AOD-9604, at doses that significantly stimulate lipolysis, does not affect glucose tolerance or insulin sensitivity, does not change serum IGF-1 levels, and does not promote long bone growth. This safety profile was a primary design objective of the fragment.

AOD-9604 has received GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient, a designation that reflects extensive safety evaluation. However, this GRAS status applies to oral food use and does not constitute approval for injectable use as a therapeutic compound. Multiple clinical trials have been conducted in humans, including a Phase IIb trial involving 300 obese patients that showed statistically significant weight loss compared to placebo over 12 weeks.

Beyond fat metabolism, emerging research has investigated AOD-9604's potential cartilage regeneration properties. Studies presented at orthopedic research conferences have demonstrated effects on chondrocyte proliferation and matrix production, suggesting potential applications in osteoarthritis and cartilage repair. This unexpected property adds another dimension to the compound's research profile beyond its primary metabolic applications.

AOD-9604 also appears to influence fat metabolism differently in different fat depots. Research suggests preferential effects on visceral and subcutaneous abdominal fat compared to peripheral fat, which could make it particularly relevant for metabolic health given that abdominal fat carries greater cardiovascular and metabolic risk.

specialist oversight for AOD-9604 is important to ensure proper metabolic assessment, monitor body composition changes accurately, and integrate the compound into a comprehensive approach that includes diet and exercise optimization.

## Mechanism of Action

### Step 1: GH C-Terminal Mimicry

AOD-9604 replicates the C-terminal fragment (176-191) of human growth hormone, specifically mimicking the structural domain responsible for GH's fat-metabolizing activity while excluding growth-promoting and diabetogenic domains.

### Step 2: Hormone-Sensitive Lipase Activation

AOD-9604 activates hormone-sensitive lipase (HSL) in adipocytes, catalyzing the breakdown of stored triglycerides into free fatty acids and glycerol for use as metabolic fuel.

### Step 3: Lipogenesis Inhibition

Simultaneously, AOD-9604 inhibits the lipogenesis pathway, the conversion of circulating fatty acids and glucose into new stored fat. This dual mechanism creates sustained net fat reduction.

### Step 4: Selective Fat Depot Action

Research indicates preferential effects on visceral and subcutaneous abdominal fat depots, the metabolically most dangerous fat locations, compared to peripheral fat, improving metabolic health markers.

### Step 5: No IGF-1 or Glucose Effects

Unlike full GH, AOD-9604 does not stimulate IGF-1 production, affect blood glucose levels, or influence insulin sensitivity, providing a fat-metabolic-only effect without hormonal side effects.

## Researched Benefits

### Targeted Lipolysis

AOD-9604 stimulates the breakdown of stored fat through HSL activation, specifically targeting the C-terminal mechanism of GH's fat metabolism. Clinical trials demonstrated statistically significant weight loss in obese patients over 12-week treatment periods.

### No Hormonal Side Effects

Unlike full growth hormone, AOD-9604 does not elevate IGF-1, does not affect blood glucose or insulin sensitivity, and does not promote growth. This safety profile was confirmed in clinical studies and reflects the fundamental design principle of isolating GH's lipolytic fragment.

### Lipogenesis Prevention

AOD-9604's dual mechanism includes inhibiting new fat formation (lipogenesis) in addition to breaking down existing fat. This prevents the common rebound effect seen with interventions that only address one side of the fat metabolism equation.

### FDA GRAS Safety Status

AOD-9604 has received GRAS (Generally Recognized As Safe) status from the FDA, reflecting extensive safety evaluation. While this applies to oral food use rather than injectable administration, it indicates a robust safety dataset that distinguishes it from many other research peptides.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 300mcg administered subcutaneously once daily, ideally in the morning on an empty stomach |
| Route | Subcutaneous injection |
| Duration | 12-20 weeks per cycle |
| Cycle Notes | AOD-9604 protocols are typically longer than other peptide cycles due to the gradual nature of fat metabolism changes. Morning fasted administration optimizes fat-burning activity. Results are typically measurable after 6-8 weeks. |
| Reconstitution | Reconstitute with bacteriostatic water. Using 5mg with 1.67mL yields 3000mcg/mL (300mcg per 0.1mL injection). Store reconstituted solution at 2-8°C and use within 25 days. |

> **Specialist note:** A specialist would establish baseline body composition measurements (DEXA scan or similar), metabolic panel including fasting glucose and lipids, and thyroid function before initiating AOD-9604. Follow-up assessments at 6-8 week intervals track progress and ensure metabolic markers remain optimal.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Lyophilized Powder |
| Amount | 5mg per vial |
| Purity | >99.0% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Sequence | Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge between Cys residues) |
| Molecular Weight | 1815.08 g/mol |
| Storage | Store lyophilized powder at -20°C. Reconstituted solution at 2-8°C. Protect from light. |
| Appearance | White lyophilized powder |

## Medical Guidance

While AOD-9604 has a favorable safety profile without IGF-1 or glucose effects, specialist oversight ensures proper metabolic assessment and rules out thyroid dysfunction, hormonal imbalances, or other medical conditions contributing to weight gain. Accurate body composition tracking (not just scale weight) requires medical-grade assessment tools, and integration with appropriate diet and exercise programming maximizes outcomes.

## Frequently Asked Questions

### How does AOD-9604 differ from growth hormone?

AOD-9604 is a fragment of growth hormone (amino acids 176-191 plus a stabilizing tyrosine), isolated specifically for GH's fat-metabolizing properties. Unlike full GH, AOD-9604 does not elevate IGF-1, does not affect blood glucose or insulin sensitivity, and does not promote bone or tissue growth. It provides the lipolytic benefits of GH without the hormonal side effects, which was the core design principle.

### What medical guidance applies to AOD-9604?

AOD-9604 is a compound studied in clinical research that should only be used under qualified medical supervision. A specialist consultation helps ensure proper metabolic assessment, rules out underlying conditions contributing to body composition issues, and provides accurate body composition tracking. A specialist would also optimize the protocol alongside diet and exercise recommendations.

### How long does it take to see results with AOD-9604?

Fat metabolism changes are gradual and typically become measurable after 6-8 weeks of consistent use. Protocols usually run 12-20 weeks to achieve meaningful body composition changes. Results vary significantly based on diet, exercise, baseline body composition, and individual metabolic rate. Medical-grade body composition analysis (DEXA scan) provides more accurate progress tracking than scale weight alone.

### Does AOD-9604 affect blood sugar levels?

No. One of AOD-9604's key advantages over full growth hormone is that it does not affect blood glucose or insulin sensitivity. This has been confirmed in clinical studies published in the Journal of Endocrinology. This safety profile makes it suitable for research in metabolic contexts where blood sugar disruption would be problematic.

### Can AOD-9604 help with cartilage repair?

Emerging research has identified potential cartilage regeneration properties for AOD-9604, including effects on chondrocyte proliferation and cartilage matrix production. Studies presented at orthopedic research conferences suggest possible applications in osteoarthritis and cartilage repair. This is an active research area, and a specialist can discuss whether these emerging findings are relevant to health goals.

## Related Compounds

- /compounds/tesamorelin
- /compounds/mots-c
- /compounds/cjc-1295-ipamorelin

## Comparisons

- /compare/aod-9604-vs-mots-c